At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Post-Mkt 07-20 19:11:51 EDT
2.79
-0.29
-9.42%
盘后2.83
+0.04+1.48%
19:08 EDT
High3.20Low2.74Vol505.32K
Open3.06D1 Closing3.08Amplitude14.94%
Mkt Cap37.74MTradable Cap24.76MTotal Shares13.53M
T/O1.46MT/O Rate5.69%Tradable Shares8.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.
Dow Jones  ·  07-15
Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.
CervoMed advances neflamapimod strategy with new DLB data
TIPRANKS  ·  07-15
CervoMed advances neflamapimod strategy with new DLB data
Cervomed Reports New Phase 2b Data Supporting Neflamapimod 50 Mg TID Dose for Planned DLB Phase 3 Trial
Reuters  ·  07-14
Cervomed Reports New Phase 2b Data Supporting Neflamapimod 50 Mg TID Dose for Planned DLB Phase 3 Trial
Cervomed Announces New Clinical, Plasma Biomarker and Imaging Data at Aaic 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (dlb)
THOMSON REUTERS  ·  07-14
Cervomed Announces New Clinical, Plasma Biomarker and Imaging Data at Aaic 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (dlb)
Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.
Dow Jones  ·  07-13
Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.
Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.
Dow Jones  ·  07-09
Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.
CervoMed completes enrollment in neflamapimod study
TIPRANKS  ·  07-09
CervoMed completes enrollment in neflamapimod study
Cervomed Completes Enrollment in Phase 2a Neflamapimod Trial for Nonfluent PPA
Reuters  ·  07-09
Cervomed Completes Enrollment in Phase 2a Neflamapimod Trial for Nonfluent PPA
Cervomed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
THOMSON REUTERS  ·  07-09
Cervomed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Cervomed - Interim Biomarker Data from Nfvppa Trial Expected Early Q4 2026
THOMSON REUTERS  ·  07-09
Cervomed - Interim Biomarker Data from Nfvppa Trial Expected Early Q4 2026
CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next
TIPRANKS  ·  07-09
CervoMed’s DLB Trial Milestone: What CRVO Investors Should Watch Next
CervoMed Files for Resale of Common Shares
MT Newswires Live  ·  07-07
CervoMed Files for Resale of Common Shares
CervoMed registers to sell 10.08M shares of common stock for holders
TIPRANKS  ·  07-07
CervoMed registers to sell 10.08M shares of common stock for holders
Cervomed - Files to Register Resale of 10.08 Mln Shares of Common Stock - SEC Filing
THOMSON REUTERS  ·  07-07
Cervomed - Files to Register Resale of 10.08 Mln Shares of Common Stock - SEC Filing
Cervomed to Present New Neflamapimod Phase 2 Data in Lewy Body Dementia at AAIC 2026
Reuters  ·  07-06
Cervomed to Present New Neflamapimod Phase 2 Data in Lewy Body Dementia at AAIC 2026
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
GlobeNewswire  ·  07-06
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO)
TIPRANKS  ·  06-25
H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO)
CervoMed Closes $10 Million Stock Offering
MT Newswires Live  ·  06-23
CervoMed Closes $10 Million Stock Offering
CervoMed Raises $10 Million in Direct Offering
TIPRANKS  ·  06-23
CervoMed Raises $10 Million in Direct Offering
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  06-23
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--